The bone marrow immune microenvironment in CML: treatment responses, treatment-free remission, and therapeutic vulnerabilities
SD Patterson, M Copland - Current Hematologic Malignancy Reports, 2023 - Springer
Abstract Purpose of Review Tyrosine kinase inhibitors (TKIs) are very successful for the
treatment of chronic myeloid leukaemia (CML) but are not curative in most patients due to …
treatment of chronic myeloid leukaemia (CML) but are not curative in most patients due to …
Targeting leukemic stem cells in chronic myeloid leukemia: Is it worth the effort?
S Soverini, S De Santis, C Monaldi, S Bruno… - International journal of …, 2021 - mdpi.com
Chronic myeloid leukemia (CML) is a classical example of stem cell cancer since it arises in
a multipotent hematopoietic stem cell upon the acquisition of the t (9; 22) chromosomal …
a multipotent hematopoietic stem cell upon the acquisition of the t (9; 22) chromosomal …
Human Wharton's Jelly Stem Cell Secretions Inhibit Human Leukemic Cell Line K562 in vitro by Inducing Cell Cycle Arrest and Apoptosis
MAH Huwaikem, G Kalamegam, G Alrefaei… - Frontiers in cell and …, 2021 - frontiersin.org
Emerging resistance to the tyrosine kinase inhibitors that target the BCR-ABL1 oncoprotein
has prompted research for novel therapeutics against chronic myeloid leukemia (CML) …
has prompted research for novel therapeutics against chronic myeloid leukemia (CML) …
Leukemia stem cells as a potential target to achieve therapy-free remission in chronic myeloid leukemia
K Ito, K Ito - Cancers, 2021 - mdpi.com
Simple Summary Leukemic stem cells represent a rare subpopulation of leukemic cells,
which not only drive leukemia initiation and progression, but also contribute to drug …
which not only drive leukemia initiation and progression, but also contribute to drug …
Combined inhibition of Bcl2 and Bcr-Abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells
M Massimino, P Vigneri, S Stella, E Tirrò… - Journal of Clinical …, 2021 - mdpi.com
Background: The management of Philadelphia Chromosome-positive (Ph+) hematological
malignancies is strictly correlated to the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) …
malignancies is strictly correlated to the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) …
[HTML][HTML] Eomesodermin in CD4+ T cells is essential for Ginkgolide K ameliorating disease progression in experimental autoimmune encephalomyelitis
S Chen, J Zhang, WB Yu, JC Zhuang… - … Journal of Biological …, 2021 - ncbi.nlm.nih.gov
Eomesodermin (Eomes), a transcription factor, could suppress the Th17 cell differentiation
and proliferation through directly binding to the promoter zone of the Rorc and Il17a gene …
and proliferation through directly binding to the promoter zone of the Rorc and Il17a gene …
Effect of myostatin gene mutation on erythrocyte osmotic fragility, hematological parameters and fatty acid composition of serum and erythrocyte membranes in piglets
HM Choe, K Gao, HJ Paek, ZB Luo, SZ Han… - Research in Veterinary …, 2022 - Elsevier
Fatty acid composition of serum and erythrocyte membrane, erythrocyte osmotic fragility and
hematological parameters were estimated with the objective of determining effects of the …
hematological parameters were estimated with the objective of determining effects of the …
Chronic myeloid leukemia: where do we stand, where can we go?
K Lewandowski… - Acta Haematologica …, 2022 - journals.viamedica.pl
Chronic myeloid leukemia: where do we stand, where can we go? Page 1 REVIEW ARTICLE
www.journals.viamedica.pl/acta_haematologica_polonica 153153 Acta Haematologica Polonica …
www.journals.viamedica.pl/acta_haematologica_polonica 153153 Acta Haematologica Polonica …
[HTML][HTML] BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells
HIGHLIGHTS•BCR-ABL promotes the formation of hematopoietic stem cells (HSPCs) from
an inducible murine embryonic stem cell model.•BCR-ABL favors the emergence and …
an inducible murine embryonic stem cell model.•BCR-ABL favors the emergence and …
Impact of tyrosine kinase inhibitors and bone morphogenetic proteins on persistent leukemic stem cell dormancy in Chronic Myeloid Leukemia patients at remission
K Arizkane - 2022 - theses.hal.science
Despite the therapeutic progress of Chronic Myeloid Leukemia (CML) due to the Tyrosine
Kinase Inhibitors (TKIs) that targets specifically BCR-ABL kinase, TKI treatment is not yet …
Kinase Inhibitors (TKIs) that targets specifically BCR-ABL kinase, TKI treatment is not yet …